Ionising radiation and free radical production form the basis for pathological cell changes in degenerative disorders such as Alzheimer’s disease and skin damage during aging. DNA strand breaks caused by oxidative stress require a rapid repair response. A novel finding enables us to promote DNA repair and increased cell viability by enhancing the activity of nuclear enzymes essential to this process. We have found that the addition of a specific existing food-derived biochemical can significantly enhance the activity of specific nuclear enzymes, which may increase the rate of DNA repair. More Information and Contact Details: PDF verison of Non-Confidential Disclosure Document

A new dense gas process has been patented for the formation of a polymer hydrogel matrix containing an active pharmaceutical ingredient to overcome the issues inherent in conventional techniques used for hydrogel preparation (these include; they are labour intensive, have a high residual solvent content, require high temperatures, ). In particular the process has been designed to overcome the problems associated with impregnation of an active ingredient into a polymer with polar characteristics and semi-crystalline nature whilst at the same time fabricating a porous polymer. The process allows for the simultaneous creation of a stable porous polymer hydrogel impregnated with an active pharmaceutical ingredient (amorphous form of the drug). More Information and Contact Details: PDF verison of Non-Confidential Disclosure Document

HepatoCell Therapeutics Pty Ltd. Is a spin-off company of NSi. They have developed a process that results in a regular supply of hepatocytes. Their product, viable hepatocytes, can be used for cell transplantation, in bioartificial liver devices, or for research purposes. More Information and Contact Details: PDF verison of Non-Confidential Disclosure Document

Professor Levon Khachigian and his team at the Centre for Vascular Research at the University of New South Wales (UNSW) were the first to deliver DNAzymes into an animal model of human disease in 1999 and have defined the field of DNAzyme therapeutics. The DNAzymes developed at UNSW are:

Dz13 has the potential to treat nodular BCC (70% of cases), thereby avoiding tissue scarring and disfiguration. More Information and Contact Details: PDF verison of Non-Confidential Disclosure Document

The technology provides an opportunity to develop an early marker diagnostic kit for ocular disease, in addition to a potential novel therapy allowing the regeneration of corneal tissue in situ. More Information and Contact Details: PDF verison of Non-Confidential Disclosure Document

This is a unique platform technology that enables the production of valuable secondary metabolites. The platform is based on the cyanobacterium Synechocystis sp. Non ribosomal synthesis allows microorganisms to produce a diverse range of novel compounds including carboxy acids, heterocyclic rings, fatty acids and non-proteinogenic modified amino acids. Most examples of these compounds are also highly resistant to physical and chemical degradation making them ideal for use as oral therapeutics. More Information and Contact Details: PDF verison of Non-Confidential Disclosure Document

Sp1, the first identified and cloned transcription factor, regulates gene expression via multiple mechanisms and has been the subject of intense study for almost 3 decades. Virtually all known genes are controlled by Sp1. The activity of Sp1 itself is regulated by phosphorylation, however, up until now, progress has been hamstrung by the lack of phospho-specific Sp1 antibodies. Researchers at UNSW have developed novel phospho-specific antibodies targeting Sp1 (pSp1Thr681 and pSp1Thr668/Ser670). These antibodies are now available for license as research reagents and/or diagnostic reagents. This is a unique resource, as phospho-specific Sp1 antibodies are not commercially available. More Information and Contact Details: PDF verison of Non-Confidential Disclosure Document

Cucurbiturils (Qs) are a family of rigid, emically and thermally robust container molecules that have many of the advantages but few of the disadvantages associated with cyclodextrins. They provide a unique opportunity in veterinary and human pharmaceuticals to develop new products and design more efficient delivery systems. More Information and Contact Details: PDF verison of Non-Confidential Disclosure Document

An opportunity exists for a Pharmaceutical or Biotechnology company to work with the University of New South Wales (UNSW)'s Centre for Vascular Research (CVR) to further develop Yin Yang 1 (YY1), a potent inhibitor of vascular smooth muscle cell and tumour cell proliferation. YY1 is a GLI-Kruppel-type zinc finger nuclear protein. It has therapeutic potential in occlusive vascular disorders and solid tumours. More Information and Contact Details: PDF version of Non-Confidential Disclosure Document